Home » Newsletters » BioWorld Science

BioWorld Science

June 7, 1996

View Archived Issues

Tachykinin NK1 antagonists described by Ciba-Geigy

More tachykinin antagonists described by Merck & Co.

Clinical trials on Diatide's Sn-117m DTPA

Controlled-release oxycodone HCl now on U.S. shelves

Pfizer reveals migraine treatment

Oclassen obtains rights to 5-MOP

Synthetic retinoid analogue cleared for U.S. market

Favorable trial results with interferon gamma-1b for atopic dermatitis and keloids

Collagen Corp. acquires distribution rights to Tissue Technologies' ePTFE implant

Glaxo Wellcome and Otsuka sign grepafloxacin licensing agreement

Kyowoa Hakko's RP-1551-2: a novel antimicrobial agent

Xoma granted U.S. patent for use of BPI

Toyama reveals antiherpes compounds

A7-183: Effective topical therapy of recurrent herpes labialis and genitalis

SmithKline Beecham's penciclovir available in U.K. market

Fluorouracil/epinephrine injectable gel approved

NSC-158393: Promising candidate for development as anti-AIDS drug

Immunostimulating whole plant product undergoes clinical trials on AIDS patients

Knoll describes antiarthritic and immunomodulator derivatives

Organon develops potent inhibitor of alpha-glucosidase I

Anika Research seeks European marketing approval for Orthovisc

Controlled-release naproxen sodium now on U.S. shelves

S-28828: 3M's imiquimod analogue

New 5-FU molecular combination merits further study

Development of AccuSite for basal cell carcinoma delayed

Ongoing evaluation of Pharmacia & Upjohn's new water-soluble camptothecin derivative

Melanogenesis inhibitor revealed

E. Merck describes immunoconjugates

Indena claims colchicine derivatives

Manufacturing agreement for Neoprobe's RIGS/ACT activated cell therapy

ISIS-5132/CGP-69846A efficacy reported in Nature Medicine

InSite Vision and Ciba Vision marketing agreement for sustained-release eyedrop formulation

Hoescht reports imidobisphosphonic acid derivatives

Fujisawa claims ACAT inhibitors

Sankyo discovers ACAT inhibitor

NO-1886 in phase II clinical trials

Amgen initiates first leptin clinical study

Sanguine's PHER-02 development

CDR-grafted type III anti-CEA MAbs identified

Diatide products in clinical trials: Techtide P280 and P748

AMPLICOR HIV-1 MONITOR granted U.S. approval

OraSure HIV-1 Western Blot Kit approved

Dynagen and Ramco Japan sign MycoDot distribution agreement

Cortecs' Helisal granted marketing clearance

Bristol-Myers Squibb describes compounds with melatonergic properties

CCD-3693 clinical trials scheduled

Compounds with high affinity for 5-HT1A and/or D2 receptors reported by E. Merck

Transdermal buspirone covered under U.S. patent

Pfizer reports neuroleptics

Asahi Chem. claims sigma-receptor ligands

Pharmacopeia and Akzo Nobel: Drug discovery collaboration

Patient enrollment for Alkermes' RMP-7 trials complete

CompuMed and the University of Massachusetts Medical Center enter agreement

Research agreement: TCPI and the University of Kansas

Neoprobe and Dow enter licensing agreement

Therapeutic Antibodies seeks London Stock Exchange listing

Genzyme Transgenics and Boehringer Mannheim reach agreement

Trials expected to begin on CoCensys' CCD-1042

Elan acquires rights to diazepam gel formulation

Cytokine polypeptides described by Immunex

CellPro and Northwestern University commence first BMT clinical trial in MS patients

Connective Therapeutics' peptide vaccine trial results presented

Botulinum toxin type A: Treatment of choice for idiopathic cervical dystonia

GR-205171: A non-peptide neurokinin NK1 antagonist

ADIR reports piperazines with affinity for sigma-receptors

BASF reports glutamate receptor antagonists

Ciba-Geigy discloses glycine-site NMDA antagonists

Clinical trials anticipated for CoCensys' and Ciba-Geigy's codeveloped EAA antagonist

Searle discloses LTA4 hydrolase inhibitors

SJC13: LPS-stimulated adhesion inhibitor

Phase III trials on Kyowa Hakko's olopatidine HCl complete

Warner-Lambert reveals indole endothelin antagonists

First chronotherapeutic agent for hypertension and angina now avaliable in U.S.

Cytel's cell adhesion inhibitor trial discontinued

Tranilast: An angiotensin II antagonist

PharmaGenics discloses oligonucleotides

Gea claims antiplatelet and fibrinolytic compounds

Cor Therapeutics' NDA for Integrilin faces FDA review

Genetics Institute readies factor IX marketing application

FDA allows initiation of clinical trials on Autologous Fibrinogen Delivery (AFD) kit

TZA-2209: A pure aromatase inhibitor

Patient enrollment initiated for SYNSORB Pk

Commencement of SYNSORB Cd phase I trial expected

Oral toxoid vaccine under development by OraVax

Single-dose hepatitis A vaccine available

Ansan and Boehringer Inglheim enter apafant agreement

NN-42-1007: First potent and selective hepatic glycogen phosphorylase inhibitor

Torii and Asahi Brewery report aldose reductase inhibitors

Zomacton, human growth hormone now available in Italy

La Jolla Cancer Research Foundation claims mammalian trophinin

Dopamine D4 receptor ligands discovered by Pfizer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...